Compare SPRO & GDHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | GDHG |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 73.8M |
| IPO Year | 2017 | 2022 |
| Metric | SPRO | GDHG |
|---|---|---|
| Price | $1.14 | $1.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 355.5K | 125.5K |
| Earning Date | 05-13-2026 | 07-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $300.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.08 | $1.06 |
| 52 Week High | $3.08 | $8.00 |
| Indicator | SPRO | GDHG |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 37.50 |
| Support Level | $1.13 | $1.06 |
| Resistance Level | $1.29 | $1.98 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 15.53 | 11.43 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, it manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants. it opearts in the Cayman Islands, PRC, BVI, and HK.